Sebela is privately held, profitable and employs more than 300 people between the United States and Ireland. Sebela is creating a leading US-focused specialty pharmaceutical company focused in the core therapeutic areas of women’s health and gastroenterology and has a broad portfolio of commercial and development stage products, including a rich pipeline with multiple product launches over the next 3 to 4 years. The company maintains a strong U.S. commercial infrastructure with 100+ field-based sales personnel promoting products to specialty physicians. Its late stage contraception programs (non-hormonal and hormonal IUDs) represent a rare opportunity for a new Women’s Health platform driven by new innovation for the marketplace.